FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057331120> ?p ?o ?g. }

• W2057331120 endingPage "6" @default.
• W2057331120 startingPage "PD1" @default.
• W2057331120 abstract "Abstract Background: mTOR inhibitors can activate p73, a pro-apoptotic member of the p53 family, and enhance the sensitivity of breast cancer cells to cisplatin and paclitaxel. Thus, we hypothesized that combined use of the mTOR inhibitor everolimus, cisplatin, and paclitaxel would have synergistic anti-tumor effects in TNBC. Methods: Patients with clinical stage II/III TNBC were assigned (2:1) to weekly cisplatin 25 mg/m2 + paclitaxel 80 mg/m2 ± daily everolimus 5 mg for 12 weeks, until definitive surgery. Biopsy specimens were obtained in 100% of patients at baseline, at day 5 of cycle 1 and at surgery. Primary endpoint was pathological complete response (pCR). The study design provided 90% power to detect a difference in pCR rate of 35% vs. 20% with a two-sided significance level equal to 0.1 (type I error) for each arm. Results: A total of 145 patients were accrued between 2009 and 2013. To date, 14 patients have not yet completed surgery, and 11 patients were not evaluable (study discontinuation due to disease progression, toxicity or withdrawal). Baseline characteristics between arms were similar and well balanced: median age was 52 (28 – 81), median breast tumor size was 2 cm (0.1 – 7.6), 72% of tumors were histologic grade III, and 70% of patients had clinical stage III disease. Clinical outcomes are summarized in Table 1. Clinical outcomesEvaluable patientsEverolimusN = 82PlaceboN = 38OverallN = 120Pathological responseN%N%N%pCR (pT0N0)293516424538Near pCR (pT1aN0)17215132218Residual disease364417455344Clinical ResponseN%N%N%CR465721556759PR232814373629SD1113381511PD220-21 Despite similar rates of pCR and clinical response in both arms, the combination of cisplatin/paclitaxel provided comparable pCR rates to anthracycline/cyclophosphamide/taxane containing regimens administered for longer periods of time. Most common adverse events are summarized in Table 2. Adverse events(%)Grade 1 and 2Grade 3 and 4 EvePlacEvePlacNeutropenia26272611Thrombocytopenia409 Anemia5975 2Rash4927 2Fatigue61753 Nausea6064 2Diarrhea30292 Dyspepsia3035 Mucositis3920 Hyperglycemia5140 2Transaminase elevation60183 Pneumonitis1 TNBC subtyping (Lehmann et al. JCI 2009), DNA mutations and alterations, as well as markers of proliferation, apoptosis, PI3K/mTOR and DNA damage response signaling will be presented. Preliminary analysis of Ki67 in a subset of tumors suggest that a reduction in Ki67 (day 5 biopsy) is associated with increased pCR rate. Tumors with androgen receptor expression exhibited a very low pCR rate. Conclusion: To our knowledge, this is the largest randomized neoadjuvant study in TNBC with a PI3K/mTOR pathway inhibitor. Results suggest that the paclitaxel/cisplatin combination is well tolerated and active in TNBC. The addition of Everolimus was associated with more adverse events and did not improve pCR or clinical response rates. A molecular signature or biomarker predictive of benefit from the paclitaxel/cisplatin combination is currently under investigation, and will be presented at the time of the meeting. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD1-6." @default.
• W2057331120 created "2016-06-24" @default.
• W2057331120 creator A5007080284 @default.
• W2057331120 creator A5009188630 @default.
• W2057331120 creator A5016259670 @default.
• W2057331120 creator A5017781933 @default.
• W2057331120 creator A5018188590 @default.
• W2057331120 creator A5021489857 @default.
• W2057331120 creator A5024446648 @default.
• W2057331120 creator A5031509981 @default.
• W2057331120 creator A5032886423 @default.
• W2057331120 creator A5034972183 @default.
• W2057331120 creator A5041766594 @default.
• W2057331120 creator A5051977006 @default.
• W2057331120 creator A5062382348 @default.
• W2057331120 creator A5066842023 @default.
• W2057331120 creator A5072274068 @default.
• W2057331120 creator A5080190252 @default.
• W2057331120 creator A5081741406 @default.
• W2057331120 date "2013-12-15" @default.
• W2057331120 modified "2023-09-26" @default.
• W2057331120 title "Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)" @default.
• W2057331120 doi "https://doi.org/10.1158/0008-5472.sabcs13-pd1-6" @default.
• W2057331120 hasPublicationYear "2013" @default.
• W2057331120 type Work @default.
• W2057331120 sameAs 2057331120 @default.
• W2057331120 citedByCount "7" @default.
• W2057331120 countsByYear W20573311202014 @default.
• W2057331120 countsByYear W20573311202016 @default.
• W2057331120 countsByYear W20573311202017 @default.
• W2057331120 countsByYear W20573311202018 @default.
• W2057331120 crossrefType "journal-article" @default.
• W2057331120 hasAuthorship W2057331120A5007080284 @default.
• W2057331120 hasAuthorship W2057331120A5009188630 @default.
• W2057331120 hasAuthorship W2057331120A5016259670 @default.
• W2057331120 hasAuthorship W2057331120A5017781933 @default.
• W2057331120 hasAuthorship W2057331120A5018188590 @default.
• W2057331120 hasAuthorship W2057331120A5021489857 @default.
• W2057331120 hasAuthorship W2057331120A5024446648 @default.
• W2057331120 hasAuthorship W2057331120A5031509981 @default.
• W2057331120 hasAuthorship W2057331120A5032886423 @default.
• W2057331120 hasAuthorship W2057331120A5034972183 @default.
• W2057331120 hasAuthorship W2057331120A5041766594 @default.
• W2057331120 hasAuthorship W2057331120A5051977006 @default.
• W2057331120 hasAuthorship W2057331120A5062382348 @default.
• W2057331120 hasAuthorship W2057331120A5066842023 @default.
• W2057331120 hasAuthorship W2057331120A5072274068 @default.
• W2057331120 hasAuthorship W2057331120A5080190252 @default.
• W2057331120 hasAuthorship W2057331120A5081741406 @default.
• W2057331120 hasConcept C121608353 @default.
• W2057331120 hasConcept C126322002 @default.
• W2057331120 hasConcept C126894567 @default.
• W2057331120 hasConcept C143998085 @default.
• W2057331120 hasConcept C146357865 @default.
• W2057331120 hasConcept C151730666 @default.
• W2057331120 hasConcept C203092338 @default.
• W2057331120 hasConcept C2776694085 @default.
• W2057331120 hasConcept C2777292972 @default.
• W2057331120 hasConcept C2778239845 @default.
• W2057331120 hasConcept C2778292576 @default.
• W2057331120 hasConcept C2779699572 @default.
• W2057331120 hasConcept C2780110267 @default.
• W2057331120 hasConcept C31760486 @default.
• W2057331120 hasConcept C530470458 @default.
• W2057331120 hasConcept C535046627 @default.
• W2057331120 hasConcept C71924100 @default.
• W2057331120 hasConcept C86803240 @default.
• W2057331120 hasConcept C90924648 @default.
• W2057331120 hasConceptScore W2057331120C121608353 @default.
• W2057331120 hasConceptScore W2057331120C126322002 @default.
• W2057331120 hasConceptScore W2057331120C126894567 @default.
• W2057331120 hasConceptScore W2057331120C143998085 @default.
• W2057331120 hasConceptScore W2057331120C146357865 @default.
• W2057331120 hasConceptScore W2057331120C151730666 @default.
• W2057331120 hasConceptScore W2057331120C203092338 @default.
• W2057331120 hasConceptScore W2057331120C2776694085 @default.
• W2057331120 hasConceptScore W2057331120C2777292972 @default.
• W2057331120 hasConceptScore W2057331120C2778239845 @default.
• W2057331120 hasConceptScore W2057331120C2778292576 @default.
• W2057331120 hasConceptScore W2057331120C2779699572 @default.
• W2057331120 hasConceptScore W2057331120C2780110267 @default.
• W2057331120 hasConceptScore W2057331120C31760486 @default.
• W2057331120 hasConceptScore W2057331120C530470458 @default.
• W2057331120 hasConceptScore W2057331120C535046627 @default.
• W2057331120 hasConceptScore W2057331120C71924100 @default.
• W2057331120 hasConceptScore W2057331120C86803240 @default.
• W2057331120 hasConceptScore W2057331120C90924648 @default.
• W2057331120 hasIssue "24_Supplement" @default.
• W2057331120 hasLocation W20573311201 @default.
• W2057331120 hasOpenAccess W2057331120 @default.
• W2057331120 hasPrimaryLocation W20573311201 @default.
• W2057331120 hasRelatedWork W1255356622 @default.
• W2057331120 hasRelatedWork W2100029565 @default.
• W2057331120 hasRelatedWork W2187491254 @default.
• W2057331120 hasRelatedWork W2358701816 @default.
• W2057331120 hasRelatedWork W2367105124 @default.
• W2057331120 hasRelatedWork W2390548009 @default.
• W2057331120 hasRelatedWork W2534174115 @default.

• next